Mirati Therapeutics Stock Defies Market Downturn with Unwavering Stability
Published on 09/25/2025 at 03:36 | Redaktion boerse-global.de
In a trading session characterized by broad market weakness, Mirati Therapeutics shares demonstrated exceptional resilience. The stock held completely flat, a notable show of strength against a 0.5% decline in the S&P 500 index.
This stability appears deeply rooted in significant advancements within the company’s oncology pipeline, which may be insulating the stock from wider market volatility.
- Adagrasib (Krazati) Momentum: The KRAS G12C inhibitor continues to progress through clinical trials. Just two days ago, the Phase 2/3 KRYSTAL-7 study received an update as it evaluates Adagrasib’s potential as a promising therapeutic option.
- Strategic Pipeline Advancement: Under Bristol Myers Squibb, development continues on assets originally from Mirati. The PRMT5 inhibitor, BMS-986504,... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
